Forx Therapeutics AG has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.
The University of California has synthesized α-synuclein (SNCA) and/or amyloid-β protein and/or microtubule-associated protein tau (PHF-tau; MAPT) propagation inhibitors reported to be useful for diagnosis and treatment of multiple system atrophy, Parkinson’s disease and Alzheimer’s disease.
Shandong Quanzhong Biomedical Technology Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of atherosclerosis, obesity, cancer, osteoarthritis, inflammatory bowel disease, fibrosis, psoriasis and Alzheimer’s disease.
Antengene Corp. Ltd. and Antengene Discovery Ltd. have divulged phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors acting as ferroptosis inducers reported to be useful for the treatment of cancer.
Scientists at Unity Health Toronto and University of British Columbia have identified aeroplysinin derivatives reported to be useful for the treatment of asthma, atherosclerosis, autoimmune disease, diabetic nephropathy and more.
Jiangsu Synthgene Biotechnology Co. Ltd. has synthesized platinum complexes acting as radiosensitizers reported to be useful for the treatment of cancer.
Voronoi Inc. has disclosed heteroaryl compounds acting as Myt1 kinase (PKMYT1) and/or Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Idorsia Pharmaceuticals Ltd. has divulged macrocyclic compounds acting as cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
RSS